NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹4,430 Cr | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr |
What is the latest Revenue of NATCO PHARMA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹4,430 Cr |
| Mar2024 | ₹3,999 Cr |
| Mar2023 | ₹2,707 Cr |
| Mar2022 | ₹1,945 Cr |
| Mar2021 | ₹2,052 Cr |
How is Revenue of NATCO PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,430 Cr | 10.77 | |
| Mar2024 | ₹3,999 Cr | 47.72 | |
| Mar2023 | ₹2,707 Cr | 39.20 | |
| Mar2022 | ₹1,945 Cr | -5.23 | |
| Mar2021 | ₹2,052 Cr | - | |
Compare Revenue of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹19,551.5 Cr | -1.8% | 7.5% | 40.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹407,083.0 Cr | -1% | -7% | -1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,971.0 Cr | 5% | -2.7% | 15.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹140,660.0 Cr | 3.2% | -6.2% | 29.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,686.0 Cr | 2.3% | -8.1% | 13.5% | Stock Analytics | |
| CIPLA | ₹99,086.7 Cr | 0.9% | -7.8% | -12.5% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -1.8% |
7.5% |
40.5% |
| SENSEX | 4.7% |
-0.1% |
3.6% |
You may also like the below Video Courses